Humana Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities

HUMANA INC (HUM) filed an SEC Form 8-K — Other Events. news release Humana Inc. 101 East Main Street Louisville, KY 40202 Humana Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities Louisville, KY - November 16, 2026 - Humana Inc. (NYSE: HUM) (“ Humana ”, “ we ”, or “ our ”) today announce

Original reporting
Published Nov 17, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 12:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$HUM
Neutral
medium confidence
Mentioned
$HUM
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$HUMNeutralMed
01

Why it matters

By setting the offer yield components (reference yields plus fixed spreads) and defining tender/series caps and proration mechanics, the filing reduces uncertainty about the economics of the debt repurchase and can shift credit and equity risk pricing into settlement.

02

Market read

The market gets explicit tender pricing terms and caps, which can drive near-term repricing of Humana’s credit profile ahead of expiration and settlement.

03

What to watch

Traders should watch whether the tender is oversubscribed versus the $800m 2031 series cap, since actual accepted principal determines the real cash outlay and credit impact.

Relevance 7/10Novelty 7/10Timing: today’s pricing terms and offer expiration at 5:00 p.m. ET, with settlement expected Nov. 18

Background

Humana previously announced cash tender offers for specified senior notes; this 8-K provides the reference yield and total consideration used to price each series.

Company-level read

Ticker impact

$HUMNeutralMedium confidence
Context

Humana discloses reference yields and total consideration for cash tender offers to repurchase multiple outstanding debt series, including a $800m cap on 2031 notes.

Expected impact

Likely modest pressure or volatility as investors reprice Humana’s leverage and funding costs based on the tender economics, with direction dependent on net cash impact versus expectations.

Evidence & confidence

The filing is a primary disclosure of tender pricing terms (reference yields, fixed spreads, total consideration) and acceptance caps, but it does not state final acceptance amounts or net proceeds, limiting certainty on equity impact.

Market effects

Provides a datapoint on insurer corporate-debt refinancing/tender behavior and current Treasury plus spread levels used in liability management.

Primarily US credit markets; limited direct regional spillover beyond US IG/HY debt sentiment.

Low; the event is company-specific and tied to US Treasury reference yields and Bloomberg reference pages.

Counterpoint

Equity impact may be limited because tender offers are liability-management rather than a new capital raise, and acceptance is subject to proration and caps.

Key entities

  • Humana Inc.

    Issuer conducting cash tender offers to repurchase specified outstanding senior notes.

  • Barclays Capital Inc.

    Dealer manager for the tender offers.

  • BofA Securities, Inc.

    Dealer manager for the tender offers.

  • PNC Capital Markets LLC

    Dealer manager for the tender offers.

  • U.S. Bancorp Investments, Inc.

    Dealer manager for the tender offers.

Related articles

$HUMMed

Humana Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities

Humana Inc. (HUM) announced pricing terms for its cash tender offers to purchase certain outstanding debt securities, totaling up to $1.5 billion. The offers include various senior notes due between 2027 and 2032, with specific acceptance priorities and caps. The total consideration per $1,000 principal amount varies by note series, ranging from $852.68 to $1,005.77. The offers expire on November 16, 2026, with a settlement date expected on November 18, 2026.

$HUMHigh

Why is Humana stock climbing today?

Humana Inc (HUM) stock rose 2.2% in pre-market trading after RBC Capital upgraded it to 'Outperform' and raised its price target to $563. The move follows Humana's Q3 2026 earnings beat, with revenue of $41.16 billion and raised full-year EPS guidance to at least $9.50. Multiple analysts have upgraded the stock, citing improving Medicare Advantage ratings and cost outlook.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$UNHHighAI 8/10

Positive Medicaid signals, open enrollment trends: Recapping major payers' Q3 results

UnitedHealth Group reported Q3 profit of $4.1B (up from $2.3B YoY) and revenue of $112.7B. CVS Health earned $2.2B (up from a $4B loss YoY) on $108.4B revenue, announcing a split of its pharmacy business. Cigna and Elevance Health each posted $1.4B profit. Centene reduced losses to $71M (from $6.6B YoY) on $50.6B revenue. Humana saw $162M profit (down from $195M) on $41.15B revenue, with positive Medicare enrollment trends.